These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 11826830)

  • 1. [Myocardial revascularization after pretreatment with the GPIIb/IIIa receptor blocker abciximab].
    Vahl CF; Kayhan N; Thomas G; Bode C; Hagl S
    Z Kardiol; 2001 Dec; 90(12):889-97. PubMed ID: 11826830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Preoperative administration of new GPIIb/IIIa inhibitors].
    Vahl CF; Kayhan N; Hagl S
    Kongressbd Dtsch Ges Chir Kongr; 2001; 118():584-8. PubMed ID: 11824321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial.
    Simoons ML;
    Lancet; 2001 Jun; 357(9272):1915-24. PubMed ID: 11425411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycoprotein IIb/IIIa inhibitors, surgery and bleeding.
    Aylward P
    Aust N Z J Med; 1998 Oct; 28(5):583-4. PubMed ID: 9847944
    [No Abstract]   [Full Text] [Related]  

  • 5. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial.
    Topol EJ;
    Lancet; 2001 Jun; 357(9272):1905-14. PubMed ID: 11425410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bleeding events with abciximab in acute coronary syndromes without early revascularization: An analysis of GUSTO IV-ACS.
    Lenderink T; Boersma E; Ruzyllo W; Widimsky P; Ohman EM; Armstrong PW; Wallentin L; Simoons ML;
    Am Heart J; 2004 May; 147(5):865-73. PubMed ID: 15131544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carotid angioplasty and stent placement: a prospective analysis of perioperative complications and impact of intravenously administered abciximab.
    Qureshi AI; Suri MF; Ali Z; Kim SH; Lanzino G; Fessler RD; Ringer AJ; Guterman LR; Hopkins LN
    Neurosurgery; 2002 Mar; 50(3):466-73; discussion 473-5. PubMed ID: 11841713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade.
    Lincoff AM; Tcheng JE; Califf RM; Kereiakes DJ; Kelly TA; Timmis GC; Kleiman NS; Booth JE; Balog C; Cabot CF; Anderson KM; Weisman HF; Topol EJ
    Circulation; 1999 Apr; 99(15):1951-8. PubMed ID: 10208997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy.
    Sane DC; Damaraju LV; Topol EJ; Cabot CF; Mascelli MA; Harrington RA; Simoons ML; Califf RM
    J Am Coll Cardiol; 2000 Jul; 36(1):75-83. PubMed ID: 10898416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    Kastrati A; Mehilli J; Schühlen H; Dirschinger J; Dotzer F; ten Berg JM; Neumann FJ; Bollwein H; Volmer C; Gawaz M; Berger PB; Schömig A;
    N Engl J Med; 2004 Jan; 350(3):232-8. PubMed ID: 14724302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emergent operation for percutaneous coronary rupture after abciximab administration.
    Roberts CS; Bocanegra NR
    Ann Thorac Surg; 2001 Jun; 71(6):2024-6. PubMed ID: 11426792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators.
    Brener SJ; Barr LA; Burchenal JE; Katz S; George BS; Jones AA; Cohen ED; Gainey PC; White HJ; Cheek HB; Moses JW; Moliterno DJ; Effron MB; Topol EJ
    Circulation; 1998 Aug; 98(8):734-41. PubMed ID: 9727542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emergency coronary artery bypass grafting in patients with acute myocardial infarction treated with glycoprotein IIb/IIIa receptor inhibitors.
    De Carlo M; Maselli D; Cortese B; Ciabatti N; Gistri R; Levantino M; Balbarini A; De Caterina R; Petronio AS
    Int J Cardiol; 2008 Jan; 123(3):229-33. PubMed ID: 17433463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic heparin concentrations augment platelet reactivity: implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonist abciximab.
    Mascelli MA; Kleiman NS; Marciniak SJ; Damaraju L; Weisman HF; Jordan RE
    Am Heart J; 2000 Apr; 139(4):696-703. PubMed ID: 10740154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication.
    Topol EJ; Ferguson JJ; Weisman HF; Tcheng JE; Ellis SG; Kleiman NS; Ivanhoe RJ; Wang AL; Miller DP; Anderson KM; Califf RM
    JAMA; 1997 Aug; 278(6):479-84. PubMed ID: 9256222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bridge to operation with the GPIIb/IIIa inhibitor abciximab in high-risk coronary patients.
    Schoenhoff F; Kayhan N; Thomas G; Haase KK; Borggrefe M; Katus HA; Hagl S; Vahl CF
    Thorac Cardiovasc Surg; 2006 Apr; 54(3):150-6. PubMed ID: 16639674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bleeding risks with abciximab after full-dose thrombolysis in rescue or urgent angioplasty for acute myocardial infarction.
    Jong P; Cohen EA; Batchelor W; Lazzam C; Kreatsoulas C; Natarajan MK; Strauss BH
    Am Heart J; 2001 Feb; 141(2):218-25. PubMed ID: 11174335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization.
    EPILOG Investigators
    N Engl J Med; 1997 Jun; 336(24):1689-96. PubMed ID: 9182212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized comparison of eptifibatide versus abciximab in primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction: results of the EVA-AMI Trial.
    Zeymer U; Margenet A; Haude M; Bode C; Lablanche JM; Heuer H; Schröder R; Kropff S; Bourkaib R; Banik N; Zahn R; Teiger E
    J Am Coll Cardiol; 2010 Aug; 56(6):463-9. PubMed ID: 20670755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surgical implications of platelet glycoprotein IIb-IIIa inhibition.
    Duke C; Grammie JS
    J Thorac Cardiovasc Surg; 1998 Dec; 116(6):1083-4. PubMed ID: 9832706
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.